Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

Abstract Background Cannabis use is an important risk factor for development of psychosis and further transition to schizophrenia. The prevalence of patients with psychosis and comorbid cannabis use (dual diagnosis) is rising with no approved specialized pharmacological treatment option. Cannabidiol...

Full description

Bibliographic Details
Main Authors: Jesper Østrup Rasmussen, Poul Jennum, Kristian Linnet, Birte Y. Glenthøj, Lone Baandrup
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Psychiatry
Subjects:
Cannabidiol
Cannabis
THC
Psychosis
Schizophrenia
Dual diagnosis
Online Access:https://doi.org/10.1186/s12888-021-03395-9

Internet

https://doi.org/10.1186/s12888-021-03395-9

Similar Items